DK3468573T3 - Behandling af clostridium difficile infektion - Google Patents

Behandling af clostridium difficile infektion Download PDF

Info

Publication number
DK3468573T3
DK3468573T3 DK17814024.0T DK17814024T DK3468573T3 DK 3468573 T3 DK3468573 T3 DK 3468573T3 DK 17814024 T DK17814024 T DK 17814024T DK 3468573 T3 DK3468573 T3 DK 3468573T3
Authority
DK
Denmark
Prior art keywords
treatment
clostridium difficile
difficile infection
infection
clostridium
Prior art date
Application number
DK17814024.0T
Other languages
English (en)
Inventor
Yun-Gi Kim
Bernat Olle
Shilpa Reddy
Jason Norman
Juan Patarroyo
Jessica Schneider
Original Assignee
Vedanta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedanta Biosciences Inc filed Critical Vedanta Biosciences Inc
Application granted granted Critical
Publication of DK3468573T3 publication Critical patent/DK3468573T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/742Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/10Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/30Feeding-stuffs specially adapted for particular animals for swines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK17814024.0T 2016-06-14 2017-06-14 Behandling af clostridium difficile infektion DK3468573T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662349914P 2016-06-14 2016-06-14
PCT/US2017/037498 WO2017218680A1 (en) 2016-06-14 2017-06-14 Treatment of clostridium difficile infection

Publications (1)

Publication Number Publication Date
DK3468573T3 true DK3468573T3 (da) 2023-10-16

Family

ID=60664224

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17814024.0T DK3468573T3 (da) 2016-06-14 2017-06-14 Behandling af clostridium difficile infektion

Country Status (12)

Country Link
US (1) US20240123000A1 (da)
EP (2) EP4282489A3 (da)
JP (2) JP7168558B2 (da)
KR (3) KR20240055124A (da)
CN (1) CN109562133A (da)
CA (2) CA3226196A1 (da)
DK (1) DK3468573T3 (da)
ES (1) ES2960053T3 (da)
FI (1) FI3468573T3 (da)
MX (2) MX2018015522A (da)
PT (1) PT3468573T (da)
WO (1) WO2017218680A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3058943C (en) 2017-04-03 2023-10-17 Gusto Global, Llc Rational design of microbial-based biotherapeutics
WO2019094837A1 (en) * 2017-11-09 2019-05-16 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
US20210121505A1 (en) * 2018-03-29 2021-04-29 Seres Therapeutics, Inc. Compositions and methods for treating inflammatory bowel diseases
SG11202012621VA (en) * 2018-06-19 2021-01-28 4D Pharma Res Ltd Dosage form comprising a live biotherapeutic product
JP2022500489A (ja) * 2018-08-17 2022-01-04 ヴェダンタ バイオサイエンシーズ インコーポレーテッドVedanta Biosciences, Inc. 腸内毒素症を減少させ、微生物叢を復元する方法
EP3858363A1 (en) 2020-01-28 2021-08-04 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Composition for treating intestinal or pulmonary diseases
US20230321163A1 (en) 2020-08-21 2023-10-12 Seoul National University R&Db Foundation Composition For Treating or Preventing Clostridium Difficile Infection
KR102296288B1 (ko) * 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102269966B1 (ko) * 2021-01-12 2021-06-28 주식회사 바이오뱅크힐링 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
JP2024504697A (ja) 2021-01-21 2024-02-01 ヴェダンタ バイオサイエンシーズ インコーポレーテッド 肝性脳症を処置するための組成物および方法
EP4294413A1 (en) * 2021-02-18 2023-12-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
JP2024518084A (ja) * 2021-05-10 2024-04-24 マイクロバ アイピー プロプライアタリー リミティド 疾患を治療するための組成物及び方法
KR102331485B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351148B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 페디오코쿠스 펜토사세우스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331483B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 류코노스톡 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331486B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 비피도박테리움 슈도카테눌라튬 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102331484B1 (ko) * 2021-08-02 2021-12-01 주식회사 바이오뱅크힐링 블라우티아 마실리엔시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351147B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351145B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 비피도박테리움 롱검 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102351146B1 (ko) * 2021-08-02 2022-01-14 주식회사 바이오뱅크힐링 페디오코쿠스 에시디락티시 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023014054A1 (ko) * 2021-08-02 2023-02-09 주식회사 바이오뱅크힐링 블라우티아 속 균주, 류코노스톡 속 균주 또는 루미노코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023014048A1 (ko) * 2021-08-02 2023-02-09 주식회사 바이오뱅크힐링 비피도박테리움 속 균주 또는 페디오코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102337995B1 (ko) * 2021-11-10 2021-12-14 주식회사 바이오뱅크힐링 아가토바쿨룸 부티리시프로두켄스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023075458A1 (ko) * 2021-10-27 2023-05-04 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102337998B1 (ko) * 2021-11-03 2021-12-14 주식회사 바이오뱅크힐링 로제부리아 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102444328B1 (ko) * 2022-03-11 2022-09-19 주식회사 바이오뱅크힐링 아나에로스티페스 하드루스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2023132628A1 (ko) * 2022-01-04 2023-07-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102365420B1 (ko) * 2022-01-04 2022-02-23 주식회사 바이오뱅크힐링 로제부리아 인테스티날리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102626400B1 (ko) * 2022-08-31 2024-01-19 주식회사 바이오뱅크힐링 도레아 론기카테나 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102620186B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 리모실락토바실러스 뮤코세 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
KR102628942B1 (ko) * 2023-08-08 2024-01-26 주식회사 바이오뱅크힐링 레비락토바실러스 브레비스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
KR102620185B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 블라우티아 호미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
CN117797176A (zh) * 2024-03-01 2024-04-02 南京大学 双胞梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132A (en) 1837-02-25 Improvement in propelling machinery by magnetism and electro-magnetism
US4205A (en) 1845-09-23 Spark-arrester
US3261761A (en) 1962-05-07 1966-07-19 Arthur W Anderson Method of freeze drying bacterial cultures
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
WO2012098358A1 (en) 2011-01-20 2012-07-26 Biopharma Technology Ltd Freeze drying method
CN104160014A (zh) * 2011-12-01 2014-11-19 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
WO2014029578A1 (en) 2012-08-24 2014-02-27 Haldor Topsøe A/S Method and catalyzed filter element with improved alkali-resistance for flue gas cleaning
CN105451561A (zh) * 2013-02-04 2016-03-30 赛里斯治疗公司 组合物和方法
MX367109B (es) * 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Also Published As

Publication number Publication date
EP3468573A4 (en) 2020-03-04
EP3468573A1 (en) 2019-04-17
KR102658297B1 (ko) 2024-04-18
PT3468573T (pt) 2023-10-16
EP3468573B1 (en) 2023-08-09
JP7168558B2 (ja) 2022-11-09
JP7483828B2 (ja) 2024-05-15
EP4282489A3 (en) 2024-01-10
CA3027917C (en) 2024-02-20
MX2018015522A (es) 2019-07-12
WO2017218680A1 (en) 2017-12-21
EP4282489A2 (en) 2023-11-29
KR20240055124A (ko) 2024-04-26
JP2023017845A (ja) 2023-02-07
US20240123000A1 (en) 2024-04-18
MX2023003461A (es) 2023-04-19
CN109562133A (zh) 2019-04-02
KR102554351B1 (ko) 2023-07-13
AU2017285211A1 (en) 2019-01-24
KR20190030687A (ko) 2019-03-22
JP2019517828A (ja) 2019-06-27
KR20230107416A (ko) 2023-07-14
CA3027917A1 (en) 2017-12-21
FI3468573T3 (fi) 2023-10-02
ES2960053T3 (es) 2024-02-29
CA3226196A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
DK3468573T3 (da) Behandling af clostridium difficile infektion
DK3785717T3 (da) Fremgangsmåder til behandling af coronaviridae-infektioner
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3461891T3 (da) Nedstrømsbehandling af en alkalisk phosphatase
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3684377T3 (da) Fremgangsmåder til behandling af hepatitis-b-infektion
DK3777855T3 (da) Fremgangsmåder til behandling af fibrotiske sygdomme
DK3154561T3 (da) Modulering af komplementaktivitet
DK3325662T3 (da) Epigenetisk inaktivering af nmt2
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3307267T3 (da) Behandling af multipel sklerose
DK3389692T3 (da) Modulatorer af komplement-aktivitet
DK3506904T3 (da) Behandling af demens
DK3318115T3 (da) Maskine til behandling af svinegylle
DK3237621T3 (da) Varianter af human alpha-galactosidase
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3201323T3 (da) Modificering af bakteriofag
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3122349T3 (da) Sammensætninger til behandling af autodigestion
DK3294893T3 (da) Bioproduktion af lentivirale vektorer